Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy — Live Feedhttps://www.live-feeds.com/feed/novartis-cites-cases-of-previously-unknown-tumors-possibly-tied-to-its-sma-gene-therapyContinuously updated, source-cited coverage. Novartis confirms tumor cases linked to Zolgensma, FDA investigatinghttps://www.live-feeds.com/feed/novartis-cites-cases-of-previously-unknown-tumors-possibly-tied-to-its-sma-gene-therapyhttps://www.live-feeds.com/feed/novartis-cites-cases-of-previously-unknown-tumors-possibly-tied-to-its-sma-gene-therapy#u189177Mon, 09 Nov 2026 22:23:33 +0000Novartis has confirmed reports of tumors in patients treated with Zolgensma, a gene therapy for spinal muscular atrophy. Multiple sources report nine total tumor cases, including two with a possible direct link to the therapy. The FDA is actively reviewing the safety of Zolgensma amid growing concerns from patient advocacy groups and healthcare providers. Regulatory scrutiny intensifies as investigators assess whether the viral vector used in the treatment may integrate into DNA and cause malignancies.Why it mattersZolgensma, approved for infants with spinal muscular atrophy, uses a modified v